Wording in the fertility, pregnancy and lactation section has been revised following updated data from the Antiretroviral Pregnancy Registry. It now states “A large amount of data on pregnant women (more than 1,000 pregnancy outcomes) indicate no malformations or foetal/neonatal toxicity associated with tenofovir disoproxil. Animal studies do not indicate reproductive toxicity. The use of tenofovir disoproxil may be considered during pregnancy, if necessary.”